{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T07:46:25Z","timestamp":1768635985766,"version":"3.49.0"},"reference-count":19,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/AuthorWarrantyLicense.v1"},{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["HHSN261201500003I"],"award-info":[{"award-number":["HHSN261201500003I"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["75N91019D00024"],"award-info":[{"award-number":["75N91019D00024"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2022,2,23]]},"abstract":"<jats:p>The SARS-CoV-2 pandemic created a crucial need for accurate serology assays to evaluate seroprevalence, contact tracing, and antiviral immune responses. The initial flood of serology assays entering the market with inadequate performance emphasized the need for independent evaluation of commercial SARS-CoV-2 antibody assays using performance evaluation panels to determine suitability for use under emergency use authorization (EUA).<\/jats:p>","DOI":"10.1128\/spectrum.01564-21","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T15:33:33Z","timestamp":1642001613000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":10,"title":["A Trans-Governmental Collaboration to Independently Evaluate SARS-CoV-2 Serology Assays"],"prefix":"10.1128","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3130-9882","authenticated-orcid":true,"given":"Ligia A.","family":"Pinto","sequence":"first","affiliation":[{"name":"Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ribhi M.","family":"Shawar","sequence":"additional","affiliation":[{"name":"U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan","family":"O\u2019Leary","sequence":"additional","affiliation":[{"name":"U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Troy J.","family":"Kemp","sequence":"additional","affiliation":[{"name":"Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Cherry","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Thornburg","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl N.","family":"Miller","sequence":"additional","affiliation":[{"name":"Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela S.","family":"Gallagher","sequence":"additional","affiliation":[{"name":"U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Stenzel","sequence":"additional","affiliation":[{"name":"U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany","family":"Schuck","sequence":"additional","affiliation":[{"name":"U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Michele","family":"Owen","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Kondratovich","sequence":"additional","affiliation":[{"name":"U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panayampalli S.","family":"Satheshkumar","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Schuh","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Lester","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Cristina","family":"Cassetti","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norman E.","family":"Sharpless","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Gitterman","sequence":"additional","affiliation":[{"name":"U.S. Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas R.","family":"Lowy","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","unstructured":"WHO. 2020. WHO COVID-19 Dashboard. Geneva: World Health Organization. https:\/\/covid19.who.int\/."},{"key":"e_1_3_3_3_2","unstructured":"HHS. 2020. Determination of Public Health Emergency on National Archives. https:\/\/www.federalregister.gov\/documents\/2020\/02\/07\/2020-02496\/determination-of-public-health-emergency."},{"key":"e_1_3_3_4_2","unstructured":"FDA. 2020. Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised). https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/policy-coronavirus-disease-2019-tests-during-public-health-emergency-revised."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2033687"},{"key":"e_1_3_3_6_2","unstructured":"FDA. 2020. Important Information on the Use of Serological (Antibody) Tests for COVID-19 - Letter to Health Care Providers. https:\/\/www.fda.gov\/medical-devices\/letters-health-care-providers\/important-information-use-serological-antibody-tests-covid-19-letter-health-care-providers."},{"key":"e_1_3_3_7_2","volume-title":"Insight into FDA\u2019s Revised Policy on Antibody Tests: prioritizing Access and Accuracy.","author":"Shah A","year":"2020","unstructured":"Shah A, Shuren J. 2020. Insight into FDA\u2019s Revised Policy on Antibody Tests: prioritizing Access and Accuracy. Silver Spring, MD: Food and Drug Administration."},{"key":"e_1_3_3_8_2","unstructured":"FDA. 2021. In Vitro Diagnostics EUAs. https:\/\/www.fda.gov\/medical-devices\/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices\/in-vitro-diagnostics-euas."},{"key":"e_1_3_3_9_2","unstructured":"FDA. 2020. U.S. Department of Health and Human Services. Food and Drug Administration. Independent Evaluations of COVID-19 Serological Tests. https:\/\/open.fda.gov\/apis\/device\/covid19serology."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2023830"},{"key":"e_1_3_3_11_2","unstructured":"Laurent L. 2020. Theranos Lessons Apply to Covid-19 Antibody Tests. on Bloomberg LP. https:\/\/www.bloomberg.com\/opinion\/articles\/2020-05-11\/coronavirus-antibody-tests-are-a-wild-west-without-a-sheriff."},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022483"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2639-4"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034201"},{"key":"e_1_3_3_15_2","unstructured":"FDA. 2021. Antibody Testing Is Not Currently Recommended to Assess Immunity After COVID-19 Vaccination: FDA Safety Communication. https:\/\/www.fda.gov\/medical-devices\/safety-communications\/antibody-testing-not-currently-recommended-assess-immunity-after-covid-19-vaccination-fda-safety."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpmc.100"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb2507"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","unstructured":"Freeman B Lester S Mills L Rasheed MAU Moye S Abiona O Hutchinson GB Morales-Betoulle M Krapinunaya I Gibbons A Chiang CF Cannon D Klena J Johnson JA Owen SM Graham BS Corbett KS Thornburg NJ. 2020. Validation of a SARS-CoV-2 spike protein ELISA for use in contact investigations and serosurveillance. bioRxiv. doi:10.1101\/2020.04.24.057323.","DOI":"10.1101\/2020.04.24.057323"},{"key":"e_1_3_3_19_2","volume-title":"CLSI. EP12-A2. User Protocol for Evaluation of Qualitative Test Performance; Approved Guideline","author":"Garrett P","year":"2008","unstructured":"Garrett P, Lasky F, Meier K. 2008. CLSI. EP12-A2. User Protocol for Evaluation of Qualitative Test Performance; Approved Guideline\u2014Second Edition, vol 28. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_20_2","volume-title":"Statistics with Confidence: confidence Intervals and Statistical Guidelines","author":"Altman D","year":"2000","unstructured":"Altman D, Machin D, Bryant T, Gardner M. 2000. Statistics with Confidence: confidence Intervals and Statistical Guidelines, 2nd Edition. BMJ Books.","edition":"2"}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.01564-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.01564-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T19:19:18Z","timestamp":1723403958000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/spectrum.01564-21"}},"subtitle":[],"editor":[{"given":"Tulip","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,2,23]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2,23]]}},"alternative-id":["10.1128\/spectrum.01564-21"],"URL":"https:\/\/doi.org\/10.1128\/spectrum.01564-21","relation":{},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,23]]},"assertion":[{"value":"2021-09-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01564-21"}}